AtriCure, Inc. (ATRC) Q3 Revenue Rose 15.0% to $154.5M

What happened

AtriCure reported third-quarter 2026 revenue of $154.5M, up 15.0% from a year earlier, and diluted earnings per share of $0.08, compared with a $0.01 loss. The company projected full-year 2026 revenue of approximately $606M–$610M.

Confirmed

Global impact / market context

Higher sales and a move from a per-share loss to a profit indicate stronger reported performance. If growth continues, it could support revenue and cash generation, while the full-year forecast gives investors a benchmark for judging whether later quarters meet management’s expectations.

Analyst inference

Growth was not uniform: the article says declining minimally invasive ablation sales partly offset U.S. growth. That mix matters because weakness in one product area can limit total revenue even when other sales expand; no prior forecast comparison was provided.

Confirmed

What to watch

1. Compare upcoming quarterly revenue with the approximately $606M–$610M full-year forecast; results below the pace needed to reach it could raise questions about sales growth. Analyst inference
2. Watch whether minimally invasive ablation sales continue to decline and whether growth elsewhere offsets them; the article identifies this product area as a partial drag. Analyst inference
3. Track reported earnings per share in later quarters against this quarter’s $0.08 profit, while distinguishing it from adjusted EBITDA, a measure excluding some costs. Analyst inference

Evidence

• Original source link unavailable